Bristol Myers Squibb (BMY) Q4 FY25 earnings call

Bristol-Myers Squibb concluded FY25 with strong execution, driven by its growth portfolio which nearly offset legacy product declines. The company is poised for a data-rich period in 2026 with multiple pivotal readouts, aiming to deliver sustainable long-term growth. Strategic cost savings and a balanced capital allocation approach support continued investment in the pipeline and business development.